Epoetin

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3155 publications

Efficacy, safety, and immunogenicity of UB-851 versus Eprex® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial: Erratum.

Efficacy, safety, and immunogenicity of UB-851 versus Eprex® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial: Erratum.

Journal: Journal of the Chinese Medical Association : JCMA
Published: March 20, 2026

After Eprex® discontinuation: Multicenter evidence for a biosimilar erythropoietin and health system resilience in Taiwan.

After Eprex® discontinuation: Multicenter evidence for a biosimilar erythropoietin and health system resilience in Taiwan.

Journal: Journal of the Chinese Medical Association : JCMA
Published: March 04, 2026

Complement-Mediated Hemolytic Anemia Triggered by Adenovirus Infection in a Pediatric Patient.

Complement-Mediated Hemolytic Anemia Triggered by Adenovirus Infection in a Pediatric Patient.

Journal: Cureus
Published: February 24, 2026

Copper Replacement: A Life-Saving Treatment.

Copper Replacement: A Life-Saving Treatment.

Journal: Cureus
Published: February 14, 2026

Chemotherapy-Free Achievement of Minimal Residual Disease in a Jehovah's Witness Patient With Ph-Negative B-ALL.

Chemotherapy-Free Achievement of Minimal Residual Disease in a Jehovah's Witness Patient With Ph-Negative B-ALL.

Journal: The American journal of case reports
Published: January 31, 2026

Use of Epoetin Alfa for Anemia of Chronic Disease in a Jehovah's Witness Teenager With Disseminated Coccidioidomycosis: A Case Report.

Use of Epoetin Alfa for Anemia of Chronic Disease in a Jehovah's Witness Teenager With Disseminated Coccidioidomycosis: A Case Report.

Journal: Cureus
Published: January 22, 2026

Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients.

Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients.

Journal: JAMA network open
Published: January 15, 2026

Efficacy, safety, and immunogenicity of UB-851 versus ® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial.

Efficacy, safety, and immunogenicity of UB-851 versus ® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial.

Journal: Journal of the Chinese Medical Association : JCMA
Published: December 15, 2025

Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.

Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.

Journal: JAMA network open
Published: November 11, 2025

Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease and Cancer-Related Anemia: A Narrative Review of Literature.

Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease and Cancer-Related Anemia: A Narrative Review of Literature.

Journal: Cureus
Published: September 29, 2025

Blood biomarkers and medication response following group psychotherapy as an add-on treatment in refractory idiopathic myelodysplasia.

Blood biomarkers and medication response following group psychotherapy as an add-on treatment in refractory idiopathic myelodysplasia.

Journal: Journal of psychosocial oncology
Published: September 23, 2025

A Rising Cluster of Erythropoietin-Associated Pure Red Cell Aplasia and Subsequent Response to Roxadustat: A Case Series.

A Rising Cluster of Erythropoietin-Associated Pure Red Cell Aplasia and Subsequent Response to Roxadustat: A Case Series.

Journal: Nephrology (Carlton, Vic.)
Published: September 18, 2025
Showing 1-12 of 3,155

Last Updated: 04/28/2026